Amid management shakeup, Akcea strikes latest antisense deal

Akcea will bank $250 million up front from a new licensing deal with Pfizer, adding to a balance sheet already fattened by a February deal with Novartis for another antisense oligonucleotide program based on Akcea's technology platform.

The deal gives Pfizer Inc. (NYSE:PFE) exclusive, worldwide rights to AKCEA-ANGPTL3-LRx, which is in Phase II testing to treat Type II diabetes, hypertriglyceridemia

Read the full 597 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE